K M C Speciality Hospitals (India) DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY24Mar 2024	FY23Mar 2023	FY22Mar 2022	FY21Mar 2021	FY20 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage					FY20 and earlierEvery year the company has filed comes with Alpha Plus.
	0.75×	0.74×	0.74×	0.71×
	1.06×	1.07×	1.05×	1.06×
	21.5%	21.6%	22.5%	16.6%
	—	1.00×	1.16×	1.17×
	—	1.60×	—	—
	—	27.4%	—	—
	—	26.7%	31.6%	34.6%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

KMCSHIL₹149.36

K M C Speciality Hospitals (India) Limited

· Pharma & Health

₹ CrorePeersDRAGARWQ KOVAI LOTUSEYE GPTHEALTH GKSL SHALBY INDRAMEDCO ARTEMISMEDMcap ₹2,439 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY21 31/03/2021	FY22 31/03/2022	FY23 31/03/2023	FY24 31/03/2024
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.71	0.74	0.74	0.75
Interest Burden (Pretax/EBIT) ×	1.06	1.05	1.07	1.06
EBIT Margin %	16.63	22.52	21.62	21.54
Asset Turnover ×	1.17	1.16	1.00	—
Financial Leverage (Assets/Equity) ×	—	—	1.60	—
ROE (5-step product, year-end total equity) %	—	—	27.42	—
ROE (owners' profit / average owners' equity) %	34.55	31.61	26.65	—

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.